Approval builds on established role of Rhapsido in CSU and highlights potential of BTK inhibition across immune-mediated ...

Community health starts with trust. See how Novartis and The Balm In Gilead are helping connect more people access cancer ...

Manju Ujjini, Head of Lead Discovery for our Global Health Biomedical Research group, discusses what’s next for his team in drug discovery Manjunatha (“Manju”) Ujjini aims to discover medicines for ...

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ...

What drives someone to dedicate their career to reimagining medicine? Three women at Novartis share their deeply personal and unique stories. For Arti, Giselle and Maria their desire for purpose began ...

Explore opportunities with Novartis below.

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. These studies ensure that an investigative medicine is effective and safe, ...

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer, Novartis US, responsible for the expansion of medicines across oncology, immunology, neurology, and cardiovascular, ...